Skip to main content
. 2022 Jan 1;42(3):500–511. doi: 10.1007/s10875-021-01181-6

Fig. 1.

Fig. 1

Subject Dispositiona. aOne subject who was screened and entered into the previous regimen phase was withdrawn at sponsor’s request prior to receiving any amount of IGSC 20% due to reported serious adverse events (non-productive cough with accompanying cyanosis, hypoxemia, interstitial pneumonitis) bRefers to the first 13 weeks of treatment cRefers to the next 39 weeks of treatment